论文部分内容阅读
目的:研究重组人血管内皮抑素联合人参皂甙Rg3对乳腺癌移植瘤生长的抑制作用。方法:取C57BL/6裸鼠作为研究对象,在颈部皮下注射乳腺癌细胞以建立乳腺癌移植瘤动物模型,随机分为A~D4组,分别注射生理盐水、重组人血管内皮抑素、人参皂苷Rg3、重组人血管内皮抑素联合人参皂苷Rg3。比较4组肿瘤生长情况、血清中血管新生因子含量、肿瘤组织中细胞周期比例以及细胞周期相关分子的表达量。结果:治疗前,4组肿瘤体积无差异;治疗后7、14、21d时,B、C、D组的肿瘤体积以及血清VEGF、bFGF含量均明显低于A组,D组的肿瘤体积以及血清VEGF、bFGF含量均明显低于B组和C组;治疗后21d时,B、C、D组的肿瘤重量、肿瘤体组织中S期、G2/M期比例以及cyclin E、CDC25A的mRNA含量和蛋白含量均低于A组,G0/G1期比例高于A组;D组的肿瘤重量、肿瘤体组织中S期、G2/M期比例以及cyclin E、CDC25A的mRNA含量和蛋白含量均低于B组和C组,G0/G1期比例低于B组和C组。结论:重组人血管内皮抑素联合人参皂甙Rg3能够更为有效的抑制乳腺癌移植瘤生长,使细胞周期停滞并下调细胞周期相关分子的表达。
Objective: To study the inhibitory effect of recombinant human endostatin combined with ginsenoside Rg3 on the growth of breast cancer xenografts. Methods: C57BL / 6 nude mice were injected subcutaneously into the neck to establish the breast cancer xenograft model. The mice were randomly divided into A ~ D4 group, injected with normal saline, recombinant human endostatin, ginseng Saponin Rg3, recombinant human endostatin combined with ginsenoside Rg3. The tumor growth, serum levels of angiogenic factors, the proportion of cell cycle in tumor tissues and the expression of cell cycle related molecules in the four groups were compared. Results: Before treatment, there was no difference in tumor volume between the 4 groups. At 7, 14 and 21 days after treatment, the tumor volume and the levels of VEGF and bFGF in group B, C and D were significantly lower than those in group A and group D VEGF and bFGF levels were significantly lower than those of B and C groups. At 21 days after treatment, the tumor weights of B, C and D groups, the proportion of S phase and G2 / M phase in tumor tissues, the mRNA levels of cyclin E and CDC25A The protein content in group D was lower than that in group A, and the proportion in G0 / G1 phase was higher than that in group A. The tumor weight, the S phase, the ratio of G2 / M, the mRNA and protein contents of cyclin E and CDC25A in group D were lower than In group B and group C, the proportion of G0 / G1 phase was lower than that of group B and C. Conclusion: Recombinant human endostatin combined with ginsenoside Rg3 can effectively inhibit the growth of breast cancer xenografts, arrest the cell cycle and down-regulate the expression of cell cycle related molecules.